Follicular Lymphoma
344
72
114
110
Key Insights
Highlights
Success Rate
65% trial completion
Published Results
80 trials with published results (23%)
Research Maturity
110 completed trials (32% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.9%
58 terminated out of 344 trials
65.5%
-21.1% vs benchmark
11%
38 trials in Phase 3/4
73%
80 of 110 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 110 completed trials
Clinical Trials (344)
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Epco, Zanu, Ritux for R/R FL or MZL
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)